ArticleAsian Pacific journal of cancer prevention : APJCP2025
Hyptolide Promotes Breast Cancer Stem Cells Apoptosis and S-phase Cell Cycle Arrest.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBreast cancer stem cells (BCSCs) develop apoptosis resistance by expressing pro and antiapoptotic proteins. The induction of apoptosis is an important mechanism of action for many anticancer agents. However, recently chemotherapy-induced chemoresistance and increased relapse phenomenon due to BCSCs population-targeted therapy failure. Therefore, treatment using a new compound was supposed to inhibit apoptosis resistance and increase the possibility of cancer apoptosis in the BCSCs population. This study aimed to investigate the effects of the hyptolide, isolate a compound from Hyptis pectinata on apoptosis induction in BCSCs.
methodsThe cytotoxic activity was analyzed using MTT assay. Annexin V-Propidium Iodide measured apoptosis under flow cytometry. Cell cycle arrest was assessed by flow cytometry. The molecular target, key protein, and molecular mechanism of hyptolide targeting BCSCs were determined by bioinformatic analysis.
resultHyptolide inhibited BCSCs cell growth with an IC50 value of 55 µg/mL. The hyptolide cytotoxic effect by apoptosis induction up to 32% through S-phase cell cycle arrest in a dose-dependent manner through regulation of SRC, EGFR, and MAPK1 signaling pathway.
conclusionTaken together, hyptolide has potential for treating BCSCs by targeting SRC, EGFR, and MAPK1 signaling. Further investigation of the molecular mechanisms involved is required to develop hyptolide as a BCSC-targeted drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.